BMGF – Gates Foundation [to 29 April 2017]
APRIL 25, 2017
Bill & Melinda Gates Foundation Statement on Intention to Create Non-Profit Medical Research Institute
SEATTLE (April 25, 2017) – The Bill & Melinda Gates Foundation intends to establish a non-profit medical research institute that will combat diseases that disproportionately impact the poor in low- and middle-income countries by accelerating progress in translational science – the process that translates promising scientific discoveries into potential medical products.
The foundation anticipates that the initial focus of the institute will be to enhance the product pipeline for malaria, tuberculosis, and enteric and diarrheal diseases. Since 1990, the global health product development pipeline has produced dozens of high-impact interventions that have helped save more than 100 million lives. The institute intends to build on this progress by capitalizing on new strategies that could increase the identification, selection, and optimization of novel candidates for drugs, vaccines, diagnostics, and medical devices.
The foundation intends to transition potentially viable interventions to product development partners, developing country manufacturers, and others to take forward into late-stage development.
It is anticipated that the institute will be co-located in the Seattle and Boston metropolitan regions and that Penny Heaton, who currently leads the foundation’s Vaccine Development and Surveillance Program, will take a senior leadership role with the institute.
The foundation is in the early stages of planning and design for the institute, and further details will be provided toward the end of 2017.
European Medicines Agency [to 29 April 2017]
European Immunisation Week: Statement of Guido Rasi, the Executive Director of the European Medicines Agency (EMA)
Immunisation has helped us to bring some major human diseases under control – smallpox, diphtheria, tetanus, yellow fever, whooping cough, polio, and measles – to name a few. Worldwide, vaccines are saving the lives of approximately nine million people every year, more than the whole population of Austria. Today, no child in Europe has to die from formerly common childhood diseases.
But we observe an increasing lack of trust in public health institutions, scientists and scientific knowledge itself in Europe and beyond. The main reason is fear, caused by unreliable sources of information and influencers that ignore solid scientific evidence.
Fear is not the only factor. People seem to have forgotten the dreadful consequences of some of the vaccine-preventable diseases.
I call on all parents to protect their children. Vaccines will keep them safe from deadly measles or cervical cancer. If your child is not immunised, this could become a threat for those who are more vulnerable: siblings who are too young to be vaccinated, elderly grandparents, classmates that have special health conditions…
Gavi [to 29 April 2017]
Partnership supports launch of malaria vaccine pilots in three African countries
Funders hail next step in the development of world’s first malaria vaccine.
Geneva, 24 April 2017 – The world’s first malaria vaccine, RTS,S, has moved a step closer to a global rollout following WHO’s announcement that Ghana, Kenya and Malawi will begin administering the vaccine in 2018.
The three countries will host pilots to evaluate the feasibility of delivering the required four doses of RTS,S in real-life settings, the vaccine’s potential role in reducing childhood deaths and its safety in the context of routine use.
Gavi, the Vaccine Alliance, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and Unitaid are partnering to provide $49.2 million for the first phase of the pilot programme.
Ministries of Health in Ghana, Kenya and Malawi will implement the pilots, in coordination with WHO.
“The world’s first malaria vaccine is a real achievement that has been 30 years in the making,” said Dr Seth Berkley, Gavi CEO. “Today’s announcement marks an important step towards potentially making it available on a global scale. Malaria places a terrible burden on many of the world’s poorest countries, claiming thousands of lives and holding back economies. These pilots are crucial to determining the impact this vaccine could have on reducing this toll.”…
Global Fund [to 29 April 2017]
Liberia and Global Fund Deepen Partnership in Building Systems for Health
26 April 2017
President Ellen Johnson Sirleaf today outlined strategic areas of partnership between Liberia and the Global Fund, stressing the need to accelerate the process of building resilient and sustainable systems for health to prevent disease outbreaks. Liberia was the epicenter of the 2014 Ebola outbreak that claimed more than 11,000 lives across West Africa.
New Global Fund Grant Aims for Malaria Elimination in the Mekong
25 April 2017
The Global Fund to Fight AIDS, Tuberculosis and Malaria will continue to support five Southeast Asian countries to expand efforts against malaria, and aim to eliminate the most deadly strain of malaria.
Partnership Supports Launch of Malaria Vaccine Pilots in Three African Countries
24 April 2017
The world’s first malaria vaccine, RTS,S, has moved a step closer to a global rollout following WHO’s announcement that Ghana, Kenya and Malawi will begin administering the vaccine in 2018.
PATH [to 29 April 2017]
Announcement | April 25, 2017
PATH Statement in Support of New Bill & Melinda Gates Foundation Medical Research Institute
“We welcome the Bill & Melinda Gates Foundation’s plans to establish a new nonprofit medical research institute to conduct integrated early-stage research and development (R&D) on key global health disease areas,” said Steve Davis, president and CEO of PATH.
“Given the many unmet needs in global health, we commend the Gates Foundation’s continued investment in early-stage R&D on vaccines, drugs, and diagnostics for urgent health priorities. We look forward to working together to accelerate the identification and development of new tools to address some of the world’s toughest health issues,” said Steve Davis.
“PATH has a rich history and robust portfolio of work on vaccines, drugs, and diagnostics. We appreciate the Gates Foundation’s continued support for PATH. We look forward to continued discussions with foundation leadership and staff, so that PATH’s efforts and expertise align with and complement the new institute’s work,” said Steve Davis.
Announcement | April 25, 2017
PATH welcomes Zambia’s commitment to eliminate malaria by 2021
PATH welcomed today’s announcement by Zambia’s Minister of Health, Dr. Chitalu Chilufya, speaking on behalf of Edgar Chagwa Lungu, the President of Zambia, commemorating World Malaria Day with the launch of an ambitious national strategy to eliminate malaria by 2021. The strategy demonstrates Zambia’s regional leadership in the malaria fight—if successful, it would be the first sub-Saharan country with significant, year-round transmission to eliminate the disease.
Announcement | April 24, 2017
PATH and GSK welcome progress toward RTS,S malaria vaccine pilot implementation with selection of countries
PATH and GSK welcome the World Health Organization’s (WHO) announcement of the countries selected to participate in the first pilot implementation of the RTS,S/AS01 malaria vaccine (also known as Mosquirix™). The pilot implementation is due to begin in 2018. The selected countries—Ghana, Kenya, and Malawi—have achieved significant reductions in malaria mortality through the deployment of currently available prevention and control measures, but still face a substantial disease burden from malaria. Each of these countries have experience with RTS,S from the large Phase 3 efficacy and safety trial of the vaccine, which concluded in early 2014.
EDCTP [to 29 April 2017]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
25 April 2017
Funding research and innovation to help end malaria
The fight against malaria has seen a decade of remarkable success and progress. It remains, however, a threat to half of the world’s population with more than 200 million new cases of malaria and claims the lives of almost half a million people every year, the majority of whom are children under five years of age. According to the WHO 2016 World Malaria Report, 92 per cent of malaria deaths occur in sub-Saharan Africa. To end this massive suffering, the current tools are not sufficient. More research and development is needed to improve the prevention and management of malaria in the context of elimination.
Under the first EDCTP programme, malaria research received a total funding of € 50.2 million for 42 projects. Since the start of the second EDCTP programme in 2014, 6 projects in malaria research have been funded so far, to a total amount of approximately € 9.5 million…
NIH [to 29 April 2017]
April 28, 2017
Zika virus persists in the central nervous system and lymph nodes of Rhesus monkeys
Virus found in tissues weeks after clearance from blood.
April 25, 2017
NIH statement on World Malaria Day — April 25, 2017
Statement of B. Fenton Hall, M.D., Ph.D., and Anthony S. Fauci, M.D., National Institute of Allergy and Infectious Diseases.
European Vaccine Initiative [to 29 April 2017]
25 April 2017
World Malaria Day 2017: End Malaria For Good
World Malaria Day is a chance to shine a spotlight on the global effort to control malaria.
UNAIDS [to 29 April 2017]
Selected Press Releases & Updates
China–Africa partnership to improve access to health-care
28 April 2017
China and Africa have come together to find new ways of improving access to health care. More than 30 Ministers of Health from across Africa joined the Vice-Premier of China Liu Yandong, and the Chinese Minister of National Health and Family Planning Commission Li Bin at the China-Africa Ministerial Conference on Health Cooperation. The event was held in Pretoria, South Africa on April 24 under the theme China-Africa Health Cooperation, From Commitments to Actions.
The Vice Premier of China talked about the long standing partnership between China and Africa in the field of health care and of China’s commitment to help build the health sector in developing countries and boost efforts for a broader future for China-Africa cooperation in health.
In his address, the UNAIDS Executive Director, Michel Sidibé, outlined three critical initiatives that need to be put in place. He said that, together with the African Union, partners should create a workforce of 2 million community health workers for Africa, learning from the Barefoot Doctors of China organization, which trains people on basic medicine to work in rural areas of China. Trilateral cooperation between China, Africa and UNAIDS should focus on disease surveillance for accelerating action to achieve Sustainable Development Goals 3. He added that UNAIDS will continue to support the scale-up of the local production of medicines and health commodities…
Campaign to raise HIV awareness among young people in ASEAN region launched
28 April 2017
A new campaign called #Live2LUV aims to promote information on sexual and reproductive health, including HIV, among young people in South-East Asian countries. UNAIDS, along with regional networks of young people, Youth Lead and Youth Voices Count, and the United Nations Children’s Fund and the United Nations Population Fund, launched the campaign during the four-day Association of Southeast Asian Nations (ASEAN) Youth Summit in Manila, Philippines, which ends on 29 April…
Fondation Merieux [to 29 April 2017]
Mission: Contribute to global health by strengthening local capacities of developing countries to reduce the impact of infectious diseases on vulnerable populations.
27 April 2017, Phnom Penh (Cambodia)
Inauguration of the Rodolphe Mérieux Laboratory in Cambodia: new capacities for this major training and scientific research platform
On April 27, was inaugurated the Rodolphe Mérieux Laboratory at the University of Health Sciences (UHS) in Cambodia.
Wellcome Trust [to 29 April 2017]
News / Published: 26 April 2017
Innovation stops women dying from severe blood loss after childbirth
A Wellcome-funded global trial has found that tranexamic acid (TXA), a drug discovered more than 50 years ago that costs about £2 a dose, reduces maternal death from bleeding by 31% if given within three hours.
The WOMAN Trial study, coordinated by the London School of Hygiene & Tropical Medicine, recruited 20,000 mothers in 193 hospitals in 21 countries. It is published today in The Lancet (opens in a new tab)…
IVI [to 29 April 2017]
27 April 2017
IVI editorial in The Korea Herald advocates for Korean leadership for global health
by IVI Director General Jerome Kim